

China Sunsine Chemical Holdings Ltd

Focus on volume growth

SINGAPORE | MATERIALS | 4Q18 RESULTS

- 4Q18 revenue and net profit met our expectation.
- Expect 50% and 28% jump in IS and TBBS sales volume in FY19 but ASP to slip.
- The 5.5 SG cents annual dividend represents a 4.3% yield.
- Due to a softer ASP outlook which translates into a lower bottom line, we revise down our TP to S\$1.55 (previously S\$1.68) and maintain our BUY recommendation. Valuations are still attractive at 6x PE (with 1/3 of the market cap in cash).

Results at a glance

ricourto at a Biar			
(RMB mn)	4Q18	4Q17	YoY (%) Comments
Revenue	770	873	(12) Decrease in overall ASP, offsetting the slight increase in sales volumes
Gross profit	249	291	(14) Lower ASP
PBT	142	196	(27) Higher overhead costs due to higher freight cost and incentive payments to sales personnel
PAT	109	132	(18) In line with the above; lower income tax rate

Source: Company, PSR

Positives

- + New capacities commenced commercial production. Two expansion projects, namely 10,000-tonne Insoluble Sulphur (IS) production line and Phase I 10,000-tonne accelerator TBBS production line, started commercial production in Nov-18 and Jan-19 respectively. Accordingly, we expect to see a respective 50% and 28% jump in IS and TBBS sales volume. As of Jan-19, the total annual capacity of rubber accelerators, IS, and anti-oxidant arrived at 97,000 tonnes (FY18: 87,000 tonnes).
- + Dividend for FY18 at a record high. The company declared a final dividend of 5.5 SG cents for FY18, representing a 21% of payout of net profit which was reported an 88% YoY jump. Based on the last closing price of S\$1.26, the dividend yield is 4.3%.

Negatives

- ASP correction extended in 4Q18. As shown in Figure 1, the ASP of each product declined to a various extent. The overall ASP in 4Q18 decreased by 15% YoY and 8% QoQ to RMB19.1k/tonne due mainly to the drop in raw materials whose average price fell by 8.8% QoQ during the same period. Hence, the price spread between end products and raw material was holding up in 4Q18, see Figure 2. Accordingly, the company's GPM decreased slightly by 4ppt to 32.3% in 4Q18.

Figure 1: Sales volume and ASP breakdown

Sales volume

(mn tonnes)	4Q18	4Q17	YoY (%)	3Q18	QoQ (%)
Accelerators	20,961	21,722	-3.5	20,824	0.7
Insoluble Sulphur	6,725	6,010	11.9	6,150	9.3
Anti-oxidant	11,850	10,665	11.1	9,906	19.6

Average selling price

(RMB/tonne)	4Q18	4Q17	YoY (%)	3Q18	QoQ (%)
Accelerators	24,693	27,511	-10.2	26,162	-5.6
Insoluble Sulphur	10,721	11,414	-6.1	11,333	-5.4
Anti-oxidant	13,932	18,012	-22.6	15,072	-7.6

Source: Company PSR

Bull AND BEAR* StocksBnB.com

4 March 2019

BUY (Maintained)

TOTAL RETURN	26.6%
TARGET PRICE	SGD 1.550
FORECAST DIV	SGD 0.045
CLOSING PRICE	SGD 1.260

COMPANY DATA

Bloomberg Code:	CSSC SP
O/S SHARES (MN) :	491
MARKET CAP (USD mn / SGD mn) :	457/619
52 - WK HI/LO (SGD) :	1.65/0.91
3M Average Daily T/O (mn) :	0.98

MAJOR SHAREHOLDERS (%)

SUCCESS MORE GROUP	59.8%
DIMENSIONAL FUND ADVISSORS LP	1.4%
KOH CHOON KONG	0.9%

PRICE PERFORMANCE (%)

	1MTH	3МТН	1YR
COMPANY	(2.3)	(2.3)	(5.8)
STI RETURN	1.1	3.6	(5.0)

PRICE VS. STI



Source: Bloomberg, PSR

KEY FINANCIALS

Y/E Dec, RMB mn	FY17	FY18	FY19e	FY20e
Revenue	2,738	3,283	3,284	3,602
Gross profit	788	1,126	1,034	1,117
PAT	341	641	538	575
P/E (x)	6.2	4.9	5.7	5.3
P/B (x)	1.2	1.3	1.1	1.0
ROE	20%	28%	20%	18%
ROA	16%	23%	17%	16%

Source: PSR

VALUATION METHOD

FCFE (Cost of Equity: 10.0%; Terminal g: 0.5%)

Chen Guangzhi Research Analyst chengz@phillip.com.sg (+65 6212 1859)

Page | 1 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

Figure 2: Price spread (accelerator/antioxidant and aniline)



Source: CEIC, PSR

Outlook

The ASP of rubber chemicals and the cost of underlying raw materials will continue to normalise in 2019, reverting to a level that both up- and down-stream players are more comfortable. On the hand, the crude oil prices are expected to recover back to US\$60/bbl to US\$70/bbl which supports chemical raw materials prices. We believe that the GPM could correct due to the increase in the market supply of products that are driven by lower prices. Meanwhile, the company has another 20,000 tonnes of TBBS production line to be established by the end of 2019. Hence, we can still look forward to the volume growth until 2020. As of Dec-18, the company had over RMB1bn (S\$200mn) cash in hand which represented around one-third of the current market capitalisation. The business which generates steady positive free cash flow will remain healthy this year.

Maintain BUY with a lower TP of S\$1.55

Due to the expected softer ASP which translates into a lower bottom line, we revise down our TP to S\$1.55 (previously S\$1.68) and maintain our BUY recommendation.

Y/E, RMB mn	FY19e	FY20e	FY21e
Net income	538	575	550
Net capex	150	130	120
Chang in net WC	2	30	73
Change in borrowing	-	-	-
FCFE	386	416	357
Beta	1.45		
Required rate of return	10.0%		
Growth	0.5%		
FX (SGD/RMB)	4.96		
TP (SGD)	1.55		

Source: PSR






Financials

Income Statement						Balance Sheet					
Y/E Dec, RMB mn	FY16	FY17	FY18	FY19e	FY20e	Y/E Dec, RMB mn	FY16	FY17	FY18	FY19e	FY20e
Revenue	2,037	2,738	3,283	3,284	3,602	ASSETS					
COGS	(1,497)	(1,950)	(2,157)	(2,249)	(2,485)	PP&E	549	662	691	728	748
Gross profit	540	788	1,126	1,034	1,117	Others	43	41	40	39	-
EBITDA	410	567	809	754	804	Total non-current assets	592	703	731	767	748
Depreciation & Amortisation	96	90	98	106	111	Cash	276	500	1,039	1,365	1,781
EBIT	314	477	712	648	693	Inventories	145	212	217	233	249
Net Finance (Expense)/Inc	(4)	-	-	-	-	Trade receivables	548	638	691	731	775
PBT	310	477	712	648	693	Others	82	75	70	66	68
Taxation	(88)	(136)	(70)	(110)	(118)	Total current assets	1,051	1,425	2,016	2,395	2,872
PAT	222	341	641	538	575	Total Assets	1,642	2,128	2,747	3,162	3,620
Per share data						LIABILITIES					
Y/E Dec	FY16	FY17	FY18	FY19e	FY20e	Trade payables	52	71	63	72	77
EPS (RMB cents)	47.7	69.4	130.5	109.5	117.1	Borrowings	-	-	-	-	-
EPS (SG cents)	10.0	14.8	25.8	22.0	23.6	Others	229	314	359	376	401
DPS (SG cents)	1.5	3.0	5.5	4.5	4.8	Total current liabilities	281	385	422	448	478
BVPS (RMB)	2.9	3.5	4.7	5.5	6.5	Borrowings	-	-	-	-	-
BVPS (SGD)	0.6	0.8	0.9	1.1	1.3	Total non-current liabilities	-	-	-	-	-
						Total Liabilities	281	385	422	448	478
Cash Flow						Total Equity	1,362	1,742	2,326	2,714	3,180
Y/E Dec, RMB mn	FY16	FY17	FY18	FY19e	FY20e						
CFO											
PBT	310	477	712	648	693	Valuation Ratios					
Adjustments	103	92	76	102	107	Y/E Dec	FY16	FY17	FY18	FY19e	FY20e
WC changes	(124)	(83)	(2)	(30)	(30)	P/E (x)	5.0	6.2	4.9	5.7	5.3
Cash generated from ops	412	569	787	750	800	P/B (x)	0.8	1.2	1.3	1.1	1.0
Others	(85)	(100)	(84)	(110)	(118)	EV/EBITDA	2.1	2.8	2.6	2.3	1.6
Cashflow from ops	327	469	703	640	682	Growth & Margins (%)					
						Growth					
CFI						Revenue	10%	46%	43%	-8%	8%
CAPEX, net	(82.0)	(208.9)	(129.5)	(150.0)	(130.0)	Gross profit	10%	46%	43%	-8%	8%
Others	2.4	3.7	4.2	4.4	4.6	EBIT	5%	52%	49%	-9%	7%
Cashflow from investments	(80)	(205)	(125)	(146)	(125)	PAT	14%	54%	88%	-16%	7%
						Margins					
CFF						GP margin	27%	29%	34%	32%	31%
Loans, net of repayments	(148)	-	-	-	-	EBIT margin	15%	17%	22%	20%	19%
Dividends	(33)	(47)	(59)	(134)	(110)	PAT margin	11%	12%	20%	16%	16%
Others	(8)	96	6	-	-	Key Ratios					
Cashflow from financing	(189)	50	(52)	(134)	(110)	ROE	16%	20%	28%	20%	18%
Net change in cash	59	314	525	360	446	ROA	13%	16%	23%	17%	16%
Effects of exchange rate	-	(9)	16	-	-	Net Debt or (Net Cash)	(276)	(500)	(1,039)	(1,365)	(1,781)
Ending cash	274	496	1,035	1,365	1,781	Gearing		Net cash		Net cash	Net cash

Source: Company, PSR





Recommendation	Rating
Buy	1
Accumulate	2
Neutral	3
Reduce	4
Sell	5
	Buy Accumulate Neutral Reduce

Remarks

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation



Contact Information (Singapore Research Team)

Head of Research

REITs

US Equity

Paul Chew - paulchewkl@phillip.com.sg

Natalie Ong - natalieongpf@phillip.com.sg

Edmund Xue – edmundxuejj@phillip.com.sg

Banking & Finance | Healthcare
Tin Min Ying – tinmy@phillip.com.sg

Oil & Gas | Energy

Chen Guangzhi - chengz@phillip.com.sg

China/HK Equity

Zheng Jieyuan - zhengjy@phillip.com.sg

Telco | Technology

research@phillip.com.sg

Research Admin

Alvin Chia - alvinchiawy@phillip.com.sg

REITs (Commercial, Retail, Healthcare) | Property

Tara Wong - tarawongsi@phillip.com.sg

SINGAPORE

Phillip Securities Pte Ltd

Raffles City Tower
250, North Bridge Road #06-00
Singapore 179101
Tel +65 6533 6001
Fax +65 6535 6631
Website: www.poems.com.sg

JAPAN

Phillip Securities Japan, Ltd.

4-2 Nihonbashi Kabuto-cho Chuo-ku, Tokyo 103-0026 Tel +81-3 3666 2101 Fax +81-3 3666 6090

Website: www.phillip.co.jp

THAILAND

Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921 Website www.phillip.co.th

UNITED STATES
Phillip Capital Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1-312 356 9000 Fax +1-312 356 9005

Website: www.phillipusa.com

INDIA

PhillipCapital (India) Private Limited

No.1, 18th Floor, Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel West, Mumbai 400-013 Maharashtra, India

Tel: +91-22-2300 2999 / Fax: +91-22-2300 2969

Website: www.phillipcapital.in

CAMBODIA
Phillip Bank Plc

Ground Floor of B-Office Centre,#61-64, Norodom Blvd Corner Street 306,Sangkat Boeung Keng Kang 1, Khan Chamkamorn, Phnom Penh, Cambodia

Tel: 855 (0) 7796 6151/855 (0) 1620 0769 Website: <u>www.phillipbank.com.kh</u> Contact Information (Regional Member Companies)
MALAYSIA

Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel +603 2162 8841 Fax +603 2166 5099

Website: www.poems.com.my

INDONESIA

PT Phillip Securities Indonesia

ANZ Tower Level 23B, Jl Jend Sudirman Kav 33A Jakarta 10220 – Indonesia Tel +62-21 5790 0800 Fax +62-21 5790 0809

Website: www.phillip.co.id

FRANCE

King & Shaxson Capital Limited

3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel +33-1 45633100

Fax +33-1 45636017

Website: www.kingandshaxson.com

AUSTRALIA

Phillip Capital Limited

Level 10, 330 Collins Street Melbourne, Victoria 3000, Australia Tel +61-03 8633 9803 Fax +61-03 8633 9899

Website: www.phillipcapital.com.au

TURKEY

PhillipCapital Menkul Degerler

Dr. Cemil Bengü Cad. Hak Is Merkezi No. 2 Kat. 6A Caglayan 34403 Istanbul, Turkey Tel: 0212 296 84 84 Fax: 0212 233 69 29

Website: www.phillipcapital.com.tr

HONG KONG

Phillip Securities (HK) Ltd

11/F United Centre 95 Queensway Hong Kong Tel +852 2277 6600 Fax +852 2868 5307

Websites: www.phillip.com.hk

CHINA

Phillip Financial Advisory (Shanghai) Co Ltd

No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200 Fax +86-21 6351 2940

Website: www.phillip.com.cn

UNITED KINGDOM
King & Shaxson Capital Limited

6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950 Fax +44-20 7626 1757

Website: www.kingandshaxson.com

SRI LANKA

Asha Phillip Securities Limited

No. 60, 5th Lane, Colombo 3, Sri Lanka Tel: (94) 11 2429 100 Fax: (94) 11 2429 199 Website: www.ashaphillip.net

DUBAI

Phillip Futures DMCC

Member of the Dubai Gold and Commodities Exchange (DGCX) Unit No 601, Plot No 58, White Crown Bldg, Sheikh Zayed Road, P.O.Box 212291 Dubai-UAE

Tel: +971-4-3325052 / Fax: + 971-4-3328895

CHINA SUNSINE CHEMICAL HOLDINGS LTD RESULTS



Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser's license under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES

Where the report contains research analyses or reports from a foreign research house, please note:

- (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
 - (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.